Top Arecoline Secrets
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To judge various intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Key demo targets were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis